{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:41:42Z","timestamp":1793479302221,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["5R01AG071810-02"],"award-info":[{"award-number":["5R01AG071810-02"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["PTCG-20-701033"],"award-info":[{"award-number":["PTCG-20-701033"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41591-026-04547-8","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:01:32Z","timestamp":1784127692000},"page":"3458-3465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer\u2019s disease: a phase 1b, randomized, double-blind trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-3429","authenticated-orcid":false,"given":"Tommaso","family":"Croese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-0803","authenticated-orcid":false,"given":"Catherine J.","family":"Mummery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Bregman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Bracha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-8795","authenticated-orcid":false,"given":"Kuti","family":"Baruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kertser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharona","family":"Raveh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Shochat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-7507","authenticated-orcid":false,"given":"Michal","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"4547_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens, P. et al. Alzheimer\u2019s disease. Lancet 397, 1577\u20131590 (2021).","journal-title":"Lancet"},{"key":"4547_CR2","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1016\/j.neuron.2022.09.007","volume":"110","author":"M Schwartz","year":"2022","unstructured":"Schwartz, M., Abellanas, M. A., Tsitsou-Kampeli, A. & Suzzi, S. The brain-immune ecosystem: implications for immunotherapy in defeating neurodegenerative diseases. Neuron 110, 3421\u20133424 (2022).","journal-title":"Neuron"},{"key":"4547_CR3","doi-asserted-by":"publisher","first-page":"eaeb1677","DOI":"10.1126\/scitranslmed.aeb1677","volume":"18","author":"M Schwartz","year":"2026","unstructured":"Schwartz, M. & Croese, T. Treating the immune system to repair the brain. Sci. Transl. Med. 18, eaeb1677 (2026).","journal-title":"Sci. Transl. Med."},{"key":"4547_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00281-022-00944-6","volume":"44","author":"KS Heavener","year":"2022","unstructured":"Heavener, K. S. & Bradshaw, E. M. The aging immune system in Alzheimer\u2019s and Parkinson\u2019s diseases. Semin. Immunopathol. 44, 649\u2013657 (2022).","journal-title":"Semin. Immunopathol."},{"key":"4547_CR5","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1038\/s41591-025-03798-1","volume":"31","author":"HS-H Oh","year":"2025","unstructured":"Oh, H. S.-H. et al. Plasma proteomics links brain and immune system aging with healthspan and longevity. Nat. Med. 31, 2703\u20132711 (2025).","journal-title":"Nat. Med."},{"key":"4547_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl1123","volume":"10","author":"P-Y Sun","year":"2024","unstructured":"Sun, P.-Y. et al. Rejuvenation of peripheral immune cells attenuates Alzheimer's disease-like pathologies and behavioral deficits in a mouse model. Sci. Adv. 10, eadl1123 (2024).","journal-title":"Sci. Adv."},{"key":"4547_CR7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nm0908-916","volume":"14","author":"GM Pasinetti","year":"2008","unstructured":"Pasinetti, G. M. Anti-inflammatory drugs fall short in Alzheimer\u2019s disease. Nat. Med. 14, 916 (2008).","journal-title":"Nat. Med."},{"key":"4547_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73227-5","volume":"10","author":"M Begemann","year":"2020","unstructured":"Begemann, M., Leon, M., van der Horn, H. J., van der Naalt, J. & Sommer, I. Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis. Sci. Rep. 10, 16179 (2020).","journal-title":"Sci. Rep."},{"key":"4547_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.100998","volume":"57","author":"A Salminen","year":"2020","unstructured":"Salminen, A. Activation of immunosuppressive network in the aging process. Ageing Res. Rev. 57, 100998 (2020).","journal-title":"Ageing Res. Rev."},{"key":"4547_CR10","doi-asserted-by":"publisher","first-page":"149480","DOI":"10.1016\/j.brainres.2025.149480","volume":"1851","author":"W Li","year":"2025","unstructured":"Li, W., Yong-Yan, X., Jia-Xin, M., Shu-Chao, G. & Li-Ping, H. Senescent microglia: the hidden culprits accelerating Alzheimer\u2019s disease. Brain Res. 1851, 149480 (2025).","journal-title":"Brain Res."},{"key":"4547_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42708-8","volume":"13","author":"JM Grayson","year":"2023","unstructured":"Grayson, J. M. et al. T cell exhaustion is associated with cognitive status and amyloid accumulation in Alzheimer\u2019s disease. Sci. Rep. 13, 15779 (2023).","journal-title":"Sci. Rep."},{"key":"4547_CR12","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1093\/brain\/awaf167","volume":"148","author":"C Rickenbach","year":"2025","unstructured":"Rickenbach, C. et al. Altered T-cell reactivity in the early stages of Alzheimer\u2019s disease. Brain 148, 3364\u20133378 (2025).","journal-title":"Brain"},{"key":"4547_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nm.4022","volume":"22","author":"K Baruch","year":"2016","unstructured":"Baruch, K. et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer\u2019s disease. Nat. Med. 22, 135\u2013137 (2016).","journal-title":"Nat. Med."},{"key":"4547_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08352-5","volume":"10","author":"N Rosenzweig","year":"2019","unstructured":"Rosenzweig, N. et al. PD-1\/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat. Commun. 10, 465 (2019).","journal-title":"Nat. Commun."},{"key":"4547_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s43587-021-00149-w","volume":"2","author":"R Dvir-Szternfeld","year":"2022","unstructured":"Dvir-Szternfeld, R. et al. Alzheimer\u2019s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis. Nat. Aging 2, 60\u201373 (2022).","journal-title":"Nat. Aging"},{"key":"4547_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13024-021-00458-z","volume":"16","author":"H Ben-Yehuda","year":"2021","unstructured":"Ben-Yehuda, H. et al. Key role of the CCR2\u2013CCL2 axis in disease modification in a mouse model of tauopathy. Mol. Neurodegener. 16, 39 (2021).","journal-title":"Mol. Neurodegener."},{"key":"4547_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fnagi.2020.00135","volume":"12","author":"K Baruch","year":"2020","unstructured":"Baruch, K. & Yoles, E. Commentary: chronic PD-1 checkpoint blockade does not affect cognition or promote tau clearance in a tauopathy mouse model. Front. Aging Neurosci. 12, 135 (2020).","journal-title":"Front. Aging Neurosci."},{"key":"4547_CR18","doi-asserted-by":"publisher","first-page":"ITC17","DOI":"10.7326\/AITC202402200","volume":"177","author":"M Ramos-Casals","year":"2024","unstructured":"Ramos-Casals, M. & Siso-Almirall, A. Immune-related adverse events of immune checkpoint inhibitors. Ann. Intern. Med. 177, ITC17\u2013ITC32 (2024).","journal-title":"Ann. Intern. Med."},{"key":"4547_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"4547_CR20","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst, A. O. et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl Acad. Sci. USA 114, 4993\u20134998 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4547_CR21","first-page":"Cd010783","volume":"2015","author":"I Arevalo-Rodriguez","year":"2015","unstructured":"Arevalo-Rodriguez, I. et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer\u2019s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst. Rev. 2015, Cd010783 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"4547_CR22","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412\u20132414 (1993).","journal-title":"Neurology"},{"key":"4547_CR23","volume":"6","author":"RJ Jutten","year":"2020","unstructured":"Jutten, R. J. et al. The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: longitudinal findings from the Catch-Cog study cohort. Alzheimers Dement.6, e12020 (2020).","journal-title":"Alzheimers Dement."},{"key":"4547_CR24","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Differential roles of Abeta42\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat. Med. 28, 2555\u20132562 (2022).","journal-title":"Nat. Med."},{"key":"4547_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4547_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"4547_CR27","doi-asserted-by":"publisher","unstructured":"Androsova, Y. et al. Systemic administration of PD-L1 blocking antibodies leads to removal of senescent microglia. Preprint at bioRxiv https:\/\/doi.org\/10.64898\/2025.12.22.695923 (2025).","DOI":"10.64898\/2025.12.22.695923"},{"key":"4547_CR28","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.15252\/emmm.201606540","volume":"8","author":"N Mattsson","year":"2016","unstructured":"Mattsson, N. et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer\u2019s disease. EMBO Mol. Med. 8, 1184\u20131196 (2016).","journal-title":"EMBO Mol. Med."},{"key":"4547_CR29","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel, C. et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 76, 1035\u20131048 (2019).","journal-title":"JAMA Neurol."},{"key":"4547_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3030","volume":"4","author":"D Frenkel","year":"2013","unstructured":"Frenkel, D. et al. Scara1 deficiency impairs clearance of soluble amyloid-beta by mononuclear phagocytes and accelerates Alzheimer\u2019s-like disease progression. Nat. Commun. 4, 2030 (2013).","journal-title":"Nat. Commun."},{"key":"4547_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"4547_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367\u2013385 (2011).","journal-title":"Alzheimers Dement."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04547-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04547-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04547-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:02:59Z","timestamp":1789480979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04547-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4547"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04547-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.C. is a consultant for ImmunoBrain Checkpoint Inc. M.S. is a co-founder and acting Chief Scientific Officer, functioning as a consultant of ImmunoBrain Checkpoint Inc. D.B., K.B., A.K. and S.R. are employees of ImmunoBrain Checkpoint Inc and hold equity or stock options in the company. C.J.M. and N.B. report research support from ImmunoBrain Checkpoint Inc paid to their institution for the conduct of the trial. E.S. received consulting fees from ImmunoBrain Checkpoint Inc for pharmacometric analyses related to this work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}